celecoxib has been researched along with Lymphangioleiomyomatosis in 1 studies
Lymphangioleiomyomatosis: A disease characterized by the progressive invasion of SMOOTH MUSCLE CELLS into the LYMPHATIC VESSELS, and the BLOOD VESSELS. The majority of the cases occur in the LUNGS of women of child-bearing age, eventually blocking the flow of air, blood, and lymph. The common symptom is shortness of breath (DYSPNEA).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| El-Chemaly, S | 1 |
| Taveira-DaSilva, A | 1 |
| Bagwe, S | 1 |
| Klonowska, K | 1 |
| Machado, T | 1 |
| Lamattina, AM | 1 |
| Goldberg, HJ | 1 |
| Jones, AM | 1 |
| Julien-Williams, P | 1 |
| Maurer, R | 1 |
| Rosas, IO | 1 |
| Henske, EP | 1 |
| Moss, J | 1 |
| Kwiatkowski, DJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC[NCT02484664] | Phase 2 | 12 participants (Actual) | Interventional | 2016-06-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
We are reporting the number of participants in this trial who had angiomyolipoma either at the beginning or end of the study. (NCT02484664)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Celecoxib | 3 |
Forced expiratory volume in 1 second (NCT02484664)
Timeframe: 1 year
| Intervention | ml (Least Squares Mean) |
|---|---|
| Celecoxib | 2583 |
Number of Participants with Adverse Events as a Measure of Safety and Tolerability in LAM patients (NCT02484664)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Celecoxib | 11 |
"St. George's Respiratory Questionnaire is a commonly used questionnaire to assess the respiratory function of an individual.~The minimum and maximyum socres on this Questionnaire are: 0 and 100. A higher score shows more limitations, so a lower score is better in terms of respiratory function.~There are no subscales. Below we are providing mean scores for all 9 participants in this trial." (NCT02484664)
Timeframe: 1 year
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Celecoxib | 20.2 |
VEGF-D serum levels (NCT02484664)
Timeframe: 6 months
| Intervention | pg/mL (Median) |
|---|---|
| Celecoxib | 656 |
1 trial available for celecoxib and Lymphangioleiomyomatosis
| Article | Year |
|---|---|
Celecoxib in lymphangioleiomyomatosis: results of a phase I clinical trial.
Topics: Adult; Celecoxib; Cyclooxygenase 2 Inhibitors; Female; Humans; Lymphangioleiomyomatosis; Male; Middl | 2020 |